Skip to main content
. 2020 Oct 21;14:3421–3426. doi: 10.2147/OPTH.S276276

Table 3.

Treatment in Pre-COVID and In-COVID Periods

Type of Injections Bevacizumab (Avastin) Aflibercept (Eylea) Ranibizumab (Lucentis) Total
Pre-COVID (Total Patients = 607)
Number of injections 475 (67.4%) 168 (23.8%) 62 (8.8%) 705
In-COVID (Total Patients = 394)
Number of injections 313 (59.8%) 160 (30.6%) 50 (9.6%) 523
Number of injections in Pre-COVID versus In-COVID P-value>0.9